Drug Profile

Research programme: eIF4E modulators - PIC Therapeutics

Alternative Names: Eukaryotic translation initiation factor 4E modulators - PIC Therapeutics

Latest Information Update: 19 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PIC Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Apoptosis stimulants; Eukaryotic initiation factor 4E modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Apr 2023 Pharmacodynamics data from preclinical studies in Breast cancer released by PIC Therapeutics
11 Apr 2022 Preclinical trials in Cancer in USA (unspecified route)
11 Apr 2022 Pharmacodynamics data from a preclinical study in Breast cancer presented at the annual meeting of American Association for Cancer Research (AACR-2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com